Abstract
Although elevated plasma plasminogen activator inhibitor 1 (PAI-1) is associated with obesity, very little is known about its tissue or cellular origin, or about the events that lead to increased PAI-1 levels under obese conditions. Since TNF-alpha is increased in rodents both during obesity and in response to endotoxin treatment, we examined the effects of these agents on PAI-1 gene expression in the adipose tissue of CB6 mice. In untreated mice, PAI-1 mRNA was detected in both mature adipocytes and in stromal vascular cells. Both TNF-alpha and endotoxin significantly increased PAI-1 mRNA in the adipose tissue, peaking at 3-8 h. In situ hybridization analysis of adipose tissue from untreated mice revealed a weak signal for PAI-1 mRNA only in the smooth muscle cells within the vascular wall. In contrast, after endotoxin or TNF-alpha treatment, PAI-1 mRNA also was detected in adipocytes and in adventitial cells of vessels. Endotoxin also induced PAI-1 in endothelial cells, while TNF-alpha additionally induced it in smooth muscle cells. Mature 3T3-L1 adipocytes in culture also expressed PAI-1 mRNA, and its rate of synthesis was also upregulated by TNF-alpha. These studies suggest that the adipose tissue itself may be an important contributor to the elevated PAI-1 levels observed in the plasma under obese conditions.
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Björntorp P. Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med. 1992 Feb;24(1):15–18. doi: 10.3109/07853899209164140. [DOI] [PubMed] [Google Scholar]
- Bone R. C. The pathogenesis of sepsis. Ann Intern Med. 1991 Sep 15;115(6):457–469. doi: 10.7326/0003-4819-115-6-457. [DOI] [PubMed] [Google Scholar]
- Carmeliet P., Stassen J. M., Schoonjans L., Ream B., van den Oord J. J., De Mol M., Mulligan R. C., Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993 Dec;92(6):2756–2760. doi: 10.1172/JCI116893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
- Colucci M., Paramo J. A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985 Mar;75(3):818–824. doi: 10.1172/JCI111777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dawson S., Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992 Aug;95(2-3):105–117. doi: 10.1016/0021-9150(92)90014-8. [DOI] [PubMed] [Google Scholar]
- DeFronzo R. A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991 Mar;14(3):173–194. doi: 10.2337/diacare.14.3.173. [DOI] [PubMed] [Google Scholar]
- Diéval J., Nguyen G., Gross S., Delobel J., Kruithof E. K. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991 Feb 1;77(3):528–532. [PubMed] [Google Scholar]
- Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
- Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
- Green H., Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell. 1975 May;5(1):19–27. doi: 10.1016/0092-8674(75)90087-2. [DOI] [PubMed] [Google Scholar]
- Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995 May;95(5):2409–2415. doi: 10.1172/JCI117936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87–91. doi: 10.1126/science.7678183. [DOI] [PubMed] [Google Scholar]
- Juhan-Vague I., Moerman B., De Cock F., Aillaud M. F., Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res. 1984 Mar 1;33(5):523–530. doi: 10.1016/0049-3848(84)90018-5. [DOI] [PubMed] [Google Scholar]
- Keeton M., Eguchi Y., Sawdey M., Ahn C., Loskutoff D. J. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol. 1993 Jan;142(1):59–70. [PMC free article] [PubMed] [Google Scholar]
- Kern P. A., Saghizadeh M., Ong J. M., Bosch R. J., Deem R., Simsolo R. B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995 May;95(5):2111–2119. doi: 10.1172/JCI117899. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knudsen B. S., Harpel P. C., Nachman R. L. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest. 1987 Oct;80(4):1082–1089. doi: 10.1172/JCI113164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kruithof E. K., Tran-Thang C., Gudinchet A., Hauert J., Nicoloso G., Genton C., Welti H., Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987 Feb;69(2):460–466. [PubMed] [Google Scholar]
- Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obes. 1991 Sep;15 (Suppl 2):53–57. [PubMed] [Google Scholar]
- Lee M. H., Vosburgh E., Anderson K., McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993 May 1;81(9):2357–2362. [PubMed] [Google Scholar]
- Lupu F., Bergonzelli G. E., Heim D. A., Cousin E., Genton C. Y., Bachmann F., Kruithof E. K. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993 Jul;13(7):1090–1100. doi: 10.1161/01.atv.13.7.1090. [DOI] [PubMed] [Google Scholar]
- McGill J. B., Schneider D. J., Arfken C. L., Lucore C. L., Sobel B. E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994 Jan;43(1):104–109. doi: 10.2337/diab.43.1.104. [DOI] [PubMed] [Google Scholar]
- Mimuro J., Schleef R. R., Loskutoff D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721–728. [PubMed] [Google Scholar]
- Nachman R. L., Hajjar K. A., Silverstein R. L., Dinarello C. A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 1986 Jun 1;163(6):1595–1600. doi: 10.1084/jem.163.6.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Potter van Loon B. J., Kluft C., Radder J. K., Blankenstein M. A., Meinders A. E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993 Aug;42(8):945–949. doi: 10.1016/0026-0495(93)90005-9. [DOI] [PubMed] [Google Scholar]
- Primrose J. N., Davies J. A., Prentice C. R., Hughes R., Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 1992 Oct 5;68(4):396–399. [PubMed] [Google Scholar]
- RODBELL M. METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. J Biol Chem. 1964 Feb;239:375–380. [PubMed] [Google Scholar]
- Reik L. M., Maines S. L., Ryan D. E., Levin W., Bandiera S., Thomas P. E. A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. J Immunol Methods. 1987 Jun 26;100(1-2):123–130. doi: 10.1016/0022-1759(87)90180-3. [DOI] [PubMed] [Google Scholar]
- Remacle C., Grégoire F. Cellular and molecular biology in the study of the physiopathology of obesity. Acta Clin Belg Suppl. 1992;14:3–12. [PubMed] [Google Scholar]
- Saks S., Rosenblum M. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. Immunol Ser. 1992;56:567–587. [PubMed] [Google Scholar]
- Sawdey M. S., Loskutoff D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991 Oct;88(4):1346–1353. doi: 10.1172/JCI115440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sawdey M., Podor T. J., Loskutoff D. J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989 Jun 25;264(18):10396–10401. [PubMed] [Google Scholar]
- Schleef R. R., Higgins D. L., Pillemer E., Levitt L. J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989 May;83(5):1747–1752. doi: 10.1172/JCI114076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schneiderman J., Sawdey M. S., Keeton M. R., Bordin G. M., Bernstein E. F., Dilley R. B., Loskutoff D. J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6998–7002. doi: 10.1073/pnas.89.15.6998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sheehan K. C., Ruddle N. H., Schreiber R. D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989 Jun 1;142(11):3884–3893. [PubMed] [Google Scholar]
- Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
- Sundell I. B., Nilsson T. K., Hallmans G., Hellsten G., Dahlén G. H. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis. 1989 Nov;80(1):9–16. doi: 10.1016/0021-9150(89)90062-2. [DOI] [PubMed] [Google Scholar]
- Takada Y., Urano T., Watanabe I., Taminato A., Yoshimi T., Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res. 1993 Sep 1;71(5):405–415. doi: 10.1016/0049-3848(93)90165-k. [DOI] [PubMed] [Google Scholar]
- Vague P., Juhan-Vague I., Chabert V., Alessi M. C., Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism. 1989 Sep;38(9):913–915. doi: 10.1016/0026-0495(89)90241-2. [DOI] [PubMed] [Google Scholar]
- Vassalli J. D., Sappino A. P., Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991 Oct;88(4):1067–1072. doi: 10.1172/JCI115405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang A. M., Doyle M. V., Mark D. F. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9717–9721. doi: 10.1073/pnas.86.24.9717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Hinsbergh V. W., Kooistra T., van den Berg E. A., Princen H. M., Fiers W., Emeis J. J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988 Nov;72(5):1467–1473. [PubMed] [Google Scholar]